| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | lanthanum carbonate (Fosrenol®) |
| Formulation | 500 mg, 750 mg and 1000 mg chewable tablet |
| Reference number | 177 |
| Indication | Treatment of hyperphosphatemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) |
| Company | Shire Pharmaceuticals Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/03/2005 |